title: Reversing Antisense Oligonucleotide Activity with a Sense Oligonucleotide Antidote: Proof of Concept Targeting Prothrombin.
abstract: The tissue half-life of second-generation antisense oligonucleotide drugs (ASOs) is generally longer than traditional small molecule therapeutics. Thus, a strategy to reverse the activity of antisense drugs is warranted in certain settings. In this study, we describe a strategy employing the administration of a complementary sense oligonucleotide antidote (SOA). As a model system we have chosen to target the coagulation factor and antithrombotic drug target, prothrombin, to assess the feasibility of this approach. ASO targeting mouse prothrombin specifically suppressed >90% hepatic prothrombin mRNA levels and circulating prothrombin protein in mice. These effects were dose- and time-dependent, and as expected produced predictable increases in anticoagulation activity [prothrombin time/activated partial thromboplastin time (PT/aPTT)]. Treatment with prothrombin SOAs resulted in a dose-dependent reversal of ASO activity, as measured by a return in prothrombin mRNA levels and thrombin activity, and normalization of aPTT and PT. The antithrombotic activity of prothrombin ASOs was demonstrated in a FeCl3-induced thrombosis mouse model, and as predicted for this target, the doses required for antithrombotic activity were also associated with increased bleeding. Treatment with SOA was able to prevent prothrombin ASO-induced bleeding in a dose-dependent manner. These studies demonstrate for the first time the utility of SOAs to selectively and specifically reverse the intracellular effects of an antisense therapy.
authors.affiliation: 1 Drug Discovery and Corporate Development, Isis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Jeff R
authors.initials: JR
authors.lastname: Crosby
authors.affiliation: 1 Drug Discovery and Corporate Development, Isis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Chenguang
authors.initials: C
authors.lastname: Zhao
authors.affiliation: 2 Prysis Biotechnologies , Shanghai, China .
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
authors.affiliation: 1 Drug Discovery and Corporate Development, Isis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: A Robert
authors.initials: AR
authors.lastname: MacLeod
authors.affiliation: 1 Drug Discovery and Corporate Development, Isis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Shuling
authors.initials: S
authors.lastname: Guo
authors.affiliation: 1 Drug Discovery and Corporate Development, Isis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Brett P
authors.initials: BP
authors.lastname: Monia
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009841:Oligonucleotides / Q000494:pharmacology*; D016376:Oligonucleotides, Antisense / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D011516:Prothrombin / Q000187:drug effects*
chemical_list: D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; D011516:Prothrombin